Difficulty: Medium
Average Score: 77%
Practice
A 62-year-old man with chronic atrial fibrillation has been treated with warfarin. He has no other chronic illnesses and is receiving no other medications long-term except for lipid-lowering agents. Results of his complete blood cell count and tests of renal and kidney function are normal. He checks his prothrombin time monthly and has kept the international normalized ratio (INR) within the therapeutic range (2-3) for the duration of his therapy with warfarin. He has heard about recent US Food and Drug Administration (FDA) approval of dabigatran, which requires no monitoring, and he would like a prescription for this new drug. Which of the following statements is true about the use of dabigatran in atrial fibrillation compared with the well-managed use of warfarin?
Correct answer
C
Rationale
Dabigatran is noninferior to well-managed warfarin in atrial fibrillation, offering no significant benefit if INR is stable (2-3), as here. Superiority (A) or inferiority (B) isn├â┬ó├óÔÇÜ┬¼├óÔÇ×┬ót shown. It├â┬ó├óÔÇÜ┬¼├óÔÇ×┬ós not approved for postoperative use (D) or mechanical valves (E), only nonvalvular AF.